natgillin/translations-raw huggingface dataset:
Repeat infusion every 24 hours for
Infuzijo ponavljajte na
Repeat infusion every 24 hours for
Infuzijo ponavljajte na vsakih 24 ur 3 do 4 dni
Repeat infusion every 24 hours for 3-4 days or
20-40 Ponovite vsakih 24 ur.
Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved.
Ponovite infuzijo vsakih 24 ur od 3 do 4 dni ali več, dokler bolečina in akutna nezmožnost ne izzvenita.
Repeat infusion every 24 hours for at least 1 day, until healing is achieved.
Ponovite i nfundiranje na vsakih 24 ur vsaj 1 dan, dokler se ne zaceli.
Repeat infusion every 8 to 24 hours
Infuzijo ponavljajte na vsakih 8 do 24 ur,
Repeat infusion every 8 to 24 hours until threat is resolved
8 - 24 ur, dokler nevarnost za
Repeat infusion every 8 to 24 hours until threat is resolved.
Ponovite infundiranje na vsakih 8 - 24 ur, dokler nevarnost ne preneha.
Repeat infusion every 8 to 24 hours until threat is resolved.
Ponovite infuzijo vsakih 8 do 24 ur, dokler grožnja ne mine.
Repeat infusion every 8-24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor VIII activity of 30% - 60% (IU/dl)
Ponovite infundiranje na vsakih 8 - 24 ur, dokler se rana zadovoljivo ne zaceli, potem nadaljujte zdravljenje še vsaj 7 dni za vzdrževanje aktivnosti FVIII 30 % - 60 % (i.e./dl).
Repeat infusion every 8-24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dl)
Ponovite infuzijo na 8 do 24 ur do ustreznega zaceljenja rane, potem
Repeat infusion every 8-24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dl).
Infuzijo ponovimo vsakih 8–24 ur, dokler se rana ustrezno ne zaceli, nato še najmanj 7 dni vzdržujemo aktivnost faktorja VIII med 30 in 60 % (i.e./dl).
Repeat infusion every 8-24 hours until adequate wound healing, then therapy for at least another 7 days.
Ponovite infuzijo vsakih 8 do 24 ur, do zadostnega celjenja rane, zatem zdravite vsaj še naslednjih 7 dni.
Repeat infusion every 8–24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a
Infuzijo ponavljajte na vsakih 8 do 24 h, dokler se rana zadostno ne zaceli, nato nadaljujte s terapijo še najmanj
Repeat injection every 12 to 24 hours for 3-4 days or more until pain and acute disability are resolved.
Injiciranje ponavljajte od 3 do 4 dni vsakih 12 do 24 ur ali več, dokler bolečina in akutna nezmožnost ne izzvenita.
Repeat injection every 12 to 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Injiciranje ponavljajte vsaj 1 dan vsakih 12 do 24 ur, dokler krvavitev, sodeč po bolečini, ne preneha ali dokler se ne zaceli.
Repeat injection every 24 to 48 hours until pain and acute disability are resolved.
Injiciranje ponavljajte vsakih 24 do 48 ur ali več, dokler bolečina in akutna nezmožnost ne izzvenita.
Repeat injections every 12 to 24 hours
Injekcije ponavljajte na
Repeat injections every 12 to 24 hours
vsakih 12 do 24 ur
Repeat injections every 12 to 24 hours
vsakih 12 do 24 ur (8 do 24 ur
Repeat injections every 8 to 24 hours
Injekcije ponavljajte na
Repeat LVEF
Ponovite meritev
Repeat one or two times.
Ponovite enkrat ali dvakrat.
REPEAT ROCKING
PONOVITE NIHANJE
Repeat Section 3 (“Before you start using your GONAL-f pre-filled pen “) through Section 4 (“Getting your GONAL-f pre-filled pen ready for injection“) with a second pen.
Ponovite poglavje 3 ("Preden začnete uporabljati svoj GONAL-f napolnjeni injekcijski peresnik") do poglavja 4 ("Priprava vašega GONAL-f napolnjenega injekcijskega peresnika za injiciranje") z drugim napolnjenim injekcijskim peresnikom.
Repeat Step 6, if more than one vial of recombinant human hyaluronidase is needed for your dose.
Ponovite 6. korak, če za vaš odmerek potrebujete več kot eno vialo rekombinantne humane hialuronidaze.
Repeat steps 1 and 2 to put a vial adapter onto the solvent vial.
Za nameščanje adapterja za vialo na vialo z vehiklom ponovite 1. in 2. korak.
Repeat steps 3 to 10 for each capsule
Ponovite postopek od 3. do 10. točke za vsako kapsulo
Repeat steps 3 to 7 in the same way until you have taken your whole dose.
Na enak način ponavljajte korake od 3 do 7, dokler ne vzamete svojega celotnega odmerka.
Repeat steps 3 to 7 in the same way until you have taken your whole dose.
Postopek opisan pod zap. št. od 3 do 7 ponavljajte na enak način, dokler ne vzamete vašega celotnega odmerka.
Repeat steps 4 to 7 to treat the other nostril.
Ponovite korake od 4 do 7 za zdravljenje na drugi nosnici.
Repeat steps 7 to 10 – gently shake the bottle to mix the rest of the medicine, then give all the rest of the liquid to the child.
Ponovite korake 7 do 10 – rahlo stresajte plastenko, da boste preostanek zdravila dobro premešali, nato pa otroku odmerite preostalo tekočino v celoti.
Repeat steps 8, 9, 10 and 11.
Ponovite 8., 9., 10. in 11. korak.
Repeat steps 9 to 12.
Ponovite 9. do 12. korak.
Repeat tests weekly and withhold dosing if there are signs of abnormal liver function (increase in bilirubin or INR), if aminotransferase levels rise above 5x ULN, or if aminotransferase levels do not fall below 3x ULN within approximately 4 weeks.
Preiskave ponavljajte vsak teden in prekinite odmerjanje, če so prisotni znaki nenormalnega jetrnega delovanja (povečana vrednost bilirubina ali INR), če se ravni aminotransferaze povišajo na 5-kratno vrednost ULN ali če ravni aminotransferaze ne padejo pod 3-kratno vrednost ULN v približno 4 tednih.
Repeat the administration after 7 days.
Aplikacijo ponovite po 7 dneh.
Repeat the application at the base of the neck in front of the shoulder blades to empty pipette.
Preostanek vsebine merilne kapalke nanesite na zgornjem delu hrbta med lopatici
Repeat the application at the base of the neck in front of the shoulder blades to empty the pipette.
Preostanek vsebine merilne kapalke nanesite na zgornjem delu hrbta med lopatici.
Repeat the first dose monitoring after the second dose of GILENYA.
Po prejemu drugega odmerka zdravila GILENYA je treba ponoviti enak postopek spremljanja kot po prvem odmerku.
Repeat the operations in point 2–7 for the appropriate number of ampoules to be thawed.
Ponovite postopek od točke 2-7, da odmrznete ustrezno število ampul.
Repeat the rolling and moving procedures (see pictures A and B) until the liquid does appear uniformly white, cloudy and aqueous.
Ponavljajte postopek vrtenja in obračanja (glejte sliki A in B), dokler ni tekočina enakomerno bela, motna in vodna.
Repeat the thawing, opening, transfer and rinsing operations for the appropriate number of ampoules to be reconstituted in the diluent; either 1 ampoule of 1,000 doses of vaccine per 200 ml of diluent (or 1 ampoule of 2,000 doses of vaccine per 400 ml of diluent) for subcutaneous administration, or 4 ampoules of 1,000 doses of vaccine per 200 ml of diluent (or 4 ampoules of 2,000 doses of vaccine per 400 ml of diluent) for in ovo administration.
Odtajanje, odpiranje in izpiranje vsebine ampule z vehiklom ponovite glede na potrebno število ampul, ali 1 ampulo s 1,000 odmerki cepiva za 200 ml vehikla (ali 1 ampulo z 2,000 odmerki cepiva za 400 ml vehikla) za vnos v podkožje ali 4 ampule s 1,000 odmerki cepiva za 200 ml vehikla (ali 4 ampule z 2,000 odmerki cepiva za 400 ml vehikla) za vnos in ovo.
Repeat the thawing, opening, transfer and rinsing operations for the appropriate number of ampoules to be reconstituted in the diluent; either 1 ampoule of 1,000 doses of vaccine per 200 ml of diluent (or 1 ampoule of 2,000 doses of vaccine per 400 ml of diluent) for subcutaneous administration, or 4 ampoules of 1,000 doses of vaccine per 200 ml of diluent (or 4 ampoules of 2,000 doses of vaccines per 400 ml of diluent) for in ovo administration.
Odtajanje, odpiranje in izpiranje vsebine ampule z vehiklom ponovite glede na potrebno število ampul, ali 1 ampulo s 1,000 odmerki cepiva za 200 ml vehikla (ali 1 ampulo z 2,000 odmerki cepiva za 400 ml vehikla) za vnos v podkožje ali 4 ampule s 1,000 odmerki cepiva za 200 ml vehikla (ali 4 ampule z 2,000 odmerki cepiva za 400 ml vehikla) za vnos in ovo.
Repeat the treatment daily for 7 consecutive days.
V naslednjih 7 dneh postopek vsak dan ponovite.
Repeat the treatment daily for 7 consecutive days.
Zdravljenje ponavljajte 7 zaporednih dni.
Repeat these steps for other lesions that need to be injected.
Ponovite te korake še na drugih spremembah, v katere morate injicirati.
Repeat these steps until all large bubbles have been removed.
Te korake ponavljajte tako dolgo, da boste odstranili vse večje zračne mehurčke.
Repeat these steps until you have removed all the large bubbles.
Te korake ponavljajte tako dolgo, da boste odstranili vse večje zračne mehurčke.
Repeat this cleaning process 3 times.
3-krat ponovite ta postopek čiščenja.
Repeat this movement at least 10 times before each injection.
Pred prvo uporabo novega napolnjenega injekcijskega peresnika to ponovite vsaj 20-krat, pred vsakim injiciranjem pa vsaj 10-krat.
Repeat this movement at least 10 times before each injection.
Pred vsakim injiciranjem to ponovite vsaj 10-krat.
Repeat this procedure for ‘P2’ and ‘P1’ (press the white button and pump) until the display changes to show the number of doses in the nasal spray (i.e.
Ponovite postopek za »P2« in »P1« (pritiskajte belo tipko in bat črpalke), dokler se vrednosti na zaslonu ne spremenijo in se prikaže število odmerkov v pršilu za nos (npr.
Repeat this step with the vial of solvent.
Ponovite ta korak z vialo vehikla.
Repeat treatment every 12 months to maintain efficacy.
Ponavljajte uporabo vsakih 12 mesecev, da se bo učinkovitost vzdrževala.
Repeat treatment every 6 months to maintain efficacy.
Ponavljajte uporabo vsakih 6 mesecev, da se bo učinkovitost vzdrževala.
Repeat until the entire calculated volume has been applied to the dog.
Ponavljajte, dokler pes ni prejel vsega izračunanega volumna.
Repeat until the liquid does appear uniformly white and cloudy.
Ponavljajte postopek vrtenja in obračanja injekcijskega peresnika, dokler ni tekočina enakomerno bela in motna.
Repeat until the liquid does appear uniformly white and cloudy.
Postopek ponavljajte, dokler tekočina ne postane enakomerno bela in motna.
Repeat with remaining white capped tubes.
Postopek ponovite s preostalima epruvetama z belima zaporkama.
Repeat-dose toxicity studies have shown that primary target organs were tissues that undergo rapid cell division: bone marrow, lymphoid tissue, testes and digestive tract.
V študijah toksičnosti ponavljajočih se odmerkov so dokazali, da so primarni ciljni organi tkiva, kjer se celice hitro delijo: kostni mozeg, limfatično tkivo, testisi in prebavne poti.
Repeat-dose toxicity studies of intramuscularly injected paliperidone palmitate and orally administered paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals.
Študije toksičnosti z večkratnimi odmerki intramuskularno injiciranega paliperidonijevega palmitata in peroralnega paliperidona na podganah in psih so večinoma pokazale farmakološke učinke, kot so sedacija ter učinki prolaktina na mlečne žleze in spolovila.
Repeat-dose toxicity studies performed in rats and dogs demonstrate dose-dependent adverse reactions affecting changes in bile duct histology (non-reversible within a 14 day recovery period), transient increase in transaminases, LDH, total bilirubin, total cholesterin, creatinine, urea and vomiting (only in dogs).
Študije toksičnosti pri ponavljajočih se odmerkih pri podganah in psih so pokazale od odmerka odvisne neželene reakcije v histologiji, ki so vplivale na spremembe histologije žolčevoda (ireverzibilne v 14-dnevnem obdobju okrevanja), prehodno zvišanje transaminaz, LDH, skupnega bilirubina, skupnega holesterina, kreatinina in sečnine ter povečano bruhanje (samo pri psih).
Repeated adjustments in dose may be required, dependent on patients’ IGF-I response.
Glede na bolnikov odziv IGF-I bo morda treba odmerek ponovno prilagoditi.
Repeated administration
Ponavljajoče dajanje
Repeated administration of infliximab (5 mg/kg at 0, 2 and 6 weeks in fistulising Crohn´s disease, 3 or
Po večkratni uporabi infliksimaba (5 mg/kg na začetku, v 2. in 6. tednu pri Crohnovi bolezni s fistulami oz.
Repeated administration of JETREA in the same eye has not been adequately studied and is therefore not recommended.
Ponavljajoče dajanje zdravila JETREA v isto oko ni zadosti preučeno, zato ga ne priporočamo.
Repeated courses of treatment with MabThera are possible.
Zdravljenje z zdravilom MabThera se lahko ponovi.
Repeated dose administration of samarium (153Sm)-EDTMP to dogs indicated a slightly longer time for depressed bone marrow and peripheral haematological parameters to recover when compared to recovery following only single dose administration.
Pokazalo se je, da - v primerjavi z enkratno aplikacijo - po ponavljajoči aplikaciji odmerka samarija (153Sm)-EDTMP pri psih traja nekoliko dlje, da se prizadeti kostni mozeg in periferni hematološki parametri spet normalizirajo.
Repeated dose toxicity and local tolerance
Toksičnost ponavljajočih se odmerkov in lokalno prenašanje
Repeated dose toxicity studies in animals identified major target organs as the liver, retina, thyroid gland and kidney.
To se sklada z opažanji študij na živalih.
Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and female reproductive system, and probably resulting from an exaggerated pharmacodynamic effect of pramipexole.
Študije toksičnosti po večkratnih odmerkih so pokazale, da pramipeksol kaže funkcionalne učinke, večinoma na osrednje živčevje in ženska rodila, ki so verjetno posledica povečanega farmakodinamičnega učinka pramipeksola.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats.
Ponavljajoče se dajanje (8 odmerjanj) petkratnega odmerka s 14-dnevnim intervalom so mlade mačke dobro prenašale.
Repeated dosing of 15 mg/kg every 3 weeks has been administered without additional adverse drug reactions.
Pri večkratnem odmerjanju 15 mg/kg vsake 3 tedne niso opazili dodatnih neželenih učinkov.
Repeated dosing of adefovir dipivoxil 10 mg daily did not influence the pharmacokinetics of adefovir.
Večkraten odmerek 10 mg dipivoksiladefovirata na dan ni vplival na farmakokinetične lastnosti adefovirja.
repeated eye surgery within a short period of time
več zaporednih kirurških posegov na očesu v kratkem času,
Repeated intermittent treatment has been studied up to 4 intermittent courses.
Pri ponavljajočem se intermitentnem zdravljenju so preučili do 4 intermitentne cikle zdravljenja.
Repeated MUGA scan or ECHO determinations of LVEF should be considered in patients with risk factors such as high cumulative exposure to prior anthracyclines or significant pre-existing cardiac disease. (See section 4.4)
Pri bolnikih z dejavniki tveganja, kot je predhodna velika kumulativna izpostavljenost antraciklinom ali pomembna obstoječa srčna bolezen, je treba pretehtati možnost ocene vrednosti LVEF s ponovljenim slikanjem MUGA ali ehokardiografijo. (Glejte poglavje 4.4.)
Repeated occurrence of malignant (cancerous) disease.
ponovni pojav malignega (rakavega) obolenja
Repeated oral administration of robenacoxib to dogs at dosages of 2–10 mg/kg for 6 months produced no change in the blood profile, with neither accumulation of robenacoxib nor enzyme induction.
Ponavljajoče se 6 mesecev trajajoče peroralno prejemanje robenakoksiba v priporočenih odmerkih 2 - 10 mg/kg telesne mase pri psih ni povzročilo sprememb v krvni sliki, akumulacije robenakoksiba ali indukcije encimov.
Repeated PK measurements after 6 to 12 months of prophylaxis treatment with Kovaltry did not indicate any relevant changes in PK characteristics after long-term treatment.
Ponavljajoče farmakokinetične meritve po 6 do 12 mesecih profilaktičnega zdravljenja z zdravilom Kovaltry niso pokazale pomembnih sprememb farmakokinetičnih parametrov po dolgotrajnem zdravljenju.
Repeated subcutaneous administration at dosages of 2–20 mg/kg produced no change in the blood profile, with neither bioaccumulation of robenacoxib nor enzyme induction.
Ponavljajoče se subkutano injiciranje odmerkov 2 - 20 mg/kg ni povzročilo sprememb v krvni sliki, bioakumulacije robenakoksiba oziroma indukcije encimov.
Repeated topical administration of tacrolimus ointment or the ointment vehicle to rats, rabbits and micropigs was associated with slight dermal changes such as erythema, oedema and papules.
Večkratno lokalno aplikacijo mazila s takrolimusom ali vehikla mazila pri podganah, kuncih in mikroprašičkih so spremljale rahle dermalne spremembe, npr. eritem, edem in papule.
Repeated treatment courses with MabThera are possible.
Zdravljenje se lahko ponovi.
Repeated treatment is indicated only if mixed infection with coccidia and nematodes, as described in section 4.2, continues to be suspected or demonstrated.
Ponovno zdravljenje je indicirano le v primeru mešanih okužb s kokcidijami in nematodi, kot je to opisano v poglavju 4.2, če še vedno obstaja sum ali potrditev okužbe.
Repeated treatment is indicated only if mixed infection with coccidia and nematodes, as described in section 4.2, is still suspected or demonstrated.
Ponovitev zdravljenja je indicirana le v primerih mešanih okužb s kokcidijami in nematodi, kot je to opisano v poglavju 4.2, če obstaja sum ali potrditev okužbe.
Repeated treatment is indicated only if mixed infections with coccidia and roundworms continue to be suspected (by the veterinarian) or demonstrated.
Ponovno zdravljenje je indicirano le v primeru mešanih okužb s kokcidijami in nematodi, če še vedno obstaja sum (veterinarjev) ali potrditev okužbe.
Repeated treatment may be considered in case of recurrent hypercalcaemia or insufficient efficacy.
Ponovitev zdravljenja pride v poštev pri ponavljajoči se hiperkalciemiji ali nezadostni učinkovitosti.
Repeated treatment may be considered in case of recurrent hypercalcaemia or insufficient efficacy.
Zdravljenje ponovimo pri ponavljajoči se hiperkalciemiji ali nezadostni učinkovitosti.
Repeated use of the medicinal product cannot be recommended.
Ponavljajoča se uporaba tega zdravila ni priporočljiva.
Repeated use of this medicine cannot be recommended.
Ponavljajoče se uporabe tega zdravila ni mogoče priporočiti.
Repeated use: Data on the re-treatment of patients with [90Y]-radiolabeled Zevalin are not available.
Ponovna uporaba: Podatki o ponovnem zdravljenju bolnikov z [90Y] označenim zdravilom Zevalin niso na voljo.
Repeated use: Data on the re-treatment of patients with [90Y]-radiolabelled Zevalin are not available.
Ponovna uporaba: Podatki o ponovnem zdravljenju bolnikov z [90Y] označenim zdravilom Zevalin niso na voljo.
Repeated-dose toxicity
Toksičnost pri ponavljajočih se odmerkih
Repeated-dose toxicity studies in dogs of up to 4 weeks’ duration and in cynomolgus monkeys of up to 9 months’ duration revealed the liver as the primary target organ of toxicity of nilotinib.
Študije toksičnosti ponovljenih odmerkov s psi, ki so trajale do 4 tedne, in z opicami vrste javanski makak, ki so trajale do 9 mesecev, so razkrile, da so glavni tarčni organ toksičnosti nilotiniba jetra.
Repeated-dose toxicity studies in rats of up to six months in duration and in dogs up to nine months in duration revealed the gastrointestinal system to be the primary target organ of toxicity of bosutinib.
Študije toksičnosti pri ponavljajočih odmerkih, ki so na podganah trajale do 6 mesecev in na psih do 9 mesecev, so pokazale, da je primarni ciljni organ toksičnosti bosutiniba prebavni sistem.
Repeated-dose toxicity studies in rats, mice and dogs revealed only effects associated with an exaggerated pharmacological action.
Študije toksičnosti pri ponavljajočih se odmerkih pri podganah, miših in psih so pokazale samo učinke, povezane s pretiranim farmakološkim delovanjem.
Repeatedly flick the top of the tube until it is clear of any liquid
Večkrat frcnite vrh tube, dokler na njem ni več tekočine
Repeatedly inject less insulin than you need.
i večkrat zapored injicirate manj insulina, kot ga potrebujete,
Repeatedly inject less insulin than you need.
če si večkrat zapored injicirate manj insulina, kot ga potrebujete,
Repeatedly take less insulin than you need.
i večkrat zapored injicirate manj insulina, kot ga potrebujete,
Repeatedly taking less insulin than you need
Veckrat zapored ste uporabili manj insulina, kot ga potrebujete.
Reperfusion injury (no or slow reflow): impaired flow in the heart arteries after they have been reopened
zadihanost reperfuzija (ni pretoka ali zmanjšan pretok): moten pretok v srčnih žilah potem, ko so bile ponovno odprte.
Repetitive contact with the product may lead to skin allergies.
Večkratni stik z izdelkom lahko povzroči kožne alergije.
Replace any unused, unopened ampoules from the strip back into the sachet to protect them from light.
Neuporabljene, neodprte ampule na traku dajte v vrečico za zagotovitev zaščite pred sončno svetlobo.
Replace blue pen cap on pen before storage.
Pred shranjevanjem na injekcijski peresnik ponovno namestite modri pokrovček peresnika.
Replace cap after use.
Brizgo shranjujte tesno zaprto.
Replace cap on pen in order to protect from light.
Za zaščito pred svetlobo na injekcijski peresnik ponovno namestite pokrovček.
Replace needle with a new needle for the intravenous infusion.
Injekcijsko iglo na injekcijski brizgi zamenjajte z novo za intravensko infundiranje.
Replace screw cap after use.
Po uporabi ponovno namestite navojno zaporko.
Replace the big outer needle cap and unscrew the needle (picture 4).
Veliki zunanji pokrovček igle namestite nazaj in iglo odvijte (slika 4).
Replace the big outer needle cap and unscrew the needle (picture 4).
Veliki zunanji pokrovček igle namestite nazaj na iglo in iglo odvijte (slika 4).
Replace the big outer needle cap and unscrew the needle (picture E).
Veliki zunanji pokrovček igle namestite nazaj in iglo odvijte (slika E).
Replace the cap on the bottle, leaving the bottle adaptor in place.
Nastavek pustite na plastenki in jo zaprite z zaporko.
Replace the cap on the bottle.
Zaprite plastenko z zaporko.
Replace the cap on the nasal spray.
Znova namestite pokrovček na nosno pršilo.
Replace the cap on the nasal spray.
Znova namestite pokrovček na pršilo za nos.
Replace the cap on the pen in order to protect from light.
Za zagotovitev zaščite pred svetlobo na injekcijski peresnik ponovno namestite pokrovček peresnika.
Replace the cap on the pen in order to protect from light.
Za zaščito pred svetlobo na injekcijski peresnik ponovno namestite pokrovček.
Replace the cap on the pen.
Peresnik pokrijte s pokrovčkom.
Replace the cap on your pen.
Injekcijski peresnik pokrijte s pokrovčkom.
Replace the cap on your pen.
Peresnik pokrijte s pokrovčkom.
Replace the cap.
Namestite zaporko.
Replace the mouthpiece and repeat steps 8,9 and 10.
Ponovno namestite ustnik in ponovite korake št.
Replace the mouthpiece and screw it on firmly until it stops.
Ponovno namestite ustnik in ga kolikor gre trdno privijte, do kamor gre.
Replace the mouthpiece.
Ponovno namestite ustnik.
Replace the needle by a new one (the new needle should have the size which you normally use for injections).
Iglo zamenjajte z novo (nova igla naj ima tako velikost kot jo običajno uporabljate za injekcije).
Replace the needle by a new one (the new needle should have the size which you normally use for injections).
Iglo zamenjajte z novo (nova igla naj ima tako velikost, kot jo običajno uporabljate za injekcije).
Replace the outer needle cap carefully.
Previdno ponovno namestite zunanji pokrovček igle.
Replace the pen cap
Znova namestite pokrovček peresnika
Replace the pen cap after each use in order to protect from light.
Po vsaki uporabi na peresnik spet namestite njegov pokrovček, da boste zdravilo zaščitili pred svetlobo.
Replace the pen cap before you throw away your Lyxumia pen.
Preden peresnik Lyxumia zavržete, nanj namestite pokrovček peresnika.
Replace the Pen Cap by lining up the Cap Clip with the Dose Indicator and pushing straight on.
Znova namestite pokrovček peresnika, tako da poravnate sponko pokrovčka s kazalnikom odmerka in pokrovček  potisnete naravnost na peresnik.